

## Aldeyra Therapeutics to Host 2019 Research & Development Day

February 12, 2019

LEXINGTON, Mass., Feb. 12, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it will host a Research & Development Day to provide an update on current late-stage ocular programs. The event will include presentations from members of the Aldeyra executive team and Dean Eliott, M.D., Stelios Evangelos Gragoudas Associate Professor of Ophthalmology at Harvard Medical School, Director of the Retina Service at Massachusetts Eye and Ear Infirmary, and Director of the Retina Fellowship at Harvard and Massachusetts Eye and Ear Infirmary. The presentations will focus on the development and commercialization plans for novel product candidates in proliferative vitreoretinopathy, dry eye disease, allergic conjunctivitis, and noninfectious anterior uveitis.

The presentations will begin at 7:30 a.m. Eastern Time on Thursday, February 28, 2019 in New York, New York.

A live webcast of the presentation and slide deck will be available via the Company's Investor Relations website at <a href="http://ir.aldeyra.com">http://ir.aldeyra.com</a>. Following the live webcast, an archived version will be available on the website until February 28, 2020.

## About Aldeyra Therapeutics

Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for proliferative vitreoretinopathy, retinal disease, post-transplant lymphoproliferative disease, autoimmune disease, metabolic disease, and cancer. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.

## **Corporate Contact:**

David McMullin Aldeyra Therapeutics, Inc. Tel: 781-761-4904 ext. 218 dmcmullin@aldeyra.com

## **Investor Contact:**

Chris Brinzey Westwicke Partners Tel: 339-970-2843

Chris.brinzey@westwicke.com

C View original content: http://www.prnewswire.com/news-releases/aldevra-therapeutics-to-host-2019-research--development-day-300793645.html

SOURCE Aldeyra Therapeutics, Inc.